Cullinan Therapeutics, Inc. CGEM Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s accrued liabilities, current?
- Cullinan Therapeutics, Inc. (CGEM) reported accrued liabilities, current of $31.92M in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s accrued liabilities, current changed year-over-year?
- Cullinan Therapeutics, Inc.'s accrued liabilities, current increased by 41.2% year-over-year, from $22.6M to $31.92M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s accrued liabilities, current has grown at a 50.7% compound annual growth rate (CAGR), from $4.64M to $36.12M.